Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06540144 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

An Extension Study Evaluating 6-week Treatment Cycles of Rozanolixizumab in Pediatric Study Participants With Generalized Myasthenia Gravis

StatusEnrolling by Invitation
PhasePhase 3
Started2024-10-08
View on ClinicalTrials.gov ↗

Amendment history

2026-08-13
Study Status, Contacts/Locations v18
Study sites10→11
2026-07-02
3 amendments v15-v17
3 re-verifications since 2026-04-09, no change to tracked fields
2026-02-26
Study Status, Contacts/Locations v14
Study sitesdetails revised at 1 of 10 sites
2025-12-05
Study Status, Contacts/Locations v13
Study sites9→10
2025-11-28
Study Status, Contacts/Locations v12
Study sites9 entries, revised
Mg0008 2034040733
Show 11 earlier versions
2025-11-06
Study Status, Contacts/Locations v11
Study sites6→9
2025-09-12
Study Status, Contacts/Locations v10
Study sites9→6
2025-07-03
Study Status, Contacts/Locations v9
Study sites8→9
2025-06-20
Study Status, Contacts/Locations v8
Study sites7→8
2025-06-06
Study Status, Contacts/Locations v7
Study sites5→7
2025-05-22
Study Status v6
Re-verified, no change to tracked fields
2025-02-13
Study Status, Contacts/Locations v5
Study sites3→5
2025-01-31
Study Identification, Study Status v4
Re-verified, no change to tracked fields
2024-12-09
Study Status v3
Primary completion date2027-12-31→2027-08-17
Completion date2027-12-31→2027-08-17
2024-12-02
Study Status, Contacts/Locations v2
Study sites2→3
2024-10-30
Not Yet Recruiting→Enrolling by Invitation Study Identification, Study Status, Study Description, Contacts/Locations v1
Trial statusNot Yet Recruiting→Enrolling by Invitation
Start dateestimated 2024-10-01→confirmed 2024-10-08
Study sites0→2
Study title-18 characters
A Phase 3 Open-labelAn Extension Study Evaluating 6-week Treatment Cycles of Rozan [...]
2024-08-01
Original filing
The purpose of the study is to assess the long term safety and tolerability of additional 6-week treatment cycles with rozanolixizumab in pediatric participants with generalized Myasthenia Gravis (gMG) aged ≥2 at the time of the Screening Visit of MG0006.
Trial Details
NCT Number NCT06540144
Lead Sponsor UCB Biopharma SRL
Conditions Generalized Myasthenia Gravis
Enrollment 12 participants
Start Date 2024-10-08
Primary Completion 2027-08-17 (estimated)
Study Completion 2027-08-17 (estimated)
Updated on ClinicalTrials.gov 2026-08-14